Burns J W & Co. Inc. NY Has $10.88 Million Holdings in Danaher Co. (NYSE:DHR)

Burns J W & Co. Inc. NY decreased its position in Danaher Co. (NYSE:DHRFree Report) by 1.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,141 shares of the conglomerate’s stock after selling 426 shares during the period. Danaher accounts for 1.4% of Burns J W & Co. Inc. NY’s investment portfolio, making the stock its 18th biggest holding. Burns J W & Co. Inc. NY’s holdings in Danaher were worth $10,882,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tsfg LLC increased its stake in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher during the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in shares of Danaher during the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research analyst reports. Stephens began coverage on shares of Danaher in a research note on Tuesday. They set an “overweight” rating and a $315.00 price target for the company. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Barclays raised their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

Read Our Latest Stock Analysis on DHR

Danaher Price Performance

Shares of NYSE DHR traded down $0.49 during mid-day trading on Friday, reaching $270.03. 1,132,669 shares of the company were exchanged, compared to its average volume of 2,759,666. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $200.01 billion, a PE ratio of 45.77, a PEG ratio of 4.55 and a beta of 0.83. The company’s 50 day moving average price is $271.07 and its 200 day moving average price is $258.56.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.05 EPS. The firm’s revenue was down 2.9% compared to the same quarter last year. Sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.